MD-clip trial

The effect of enhanced prism spectacles on Quality of Life in patients with severe macular degeneration, a Randomized Controlled Trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27967

Enrollment

160

Registered

2016-11-11

Start date

2014-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients experiencing severe irreversible vision loss as a result of age-related macular degeneration (ARMD)

Interventions

The experimental groups wears the MD-clip 3 weeks, the control group receive the MD-Clip after the study

Eligibility

Inclusion criteria

Inclusion criteria: - diagnosis of age-related macular degeneration (AMD) - aged at least 18 years - signed informed consent.

Exclusion criteria

Exclusion criteria: - insufficient capacities of the Dutch language - handicaps impeding participation

Design outcomes

Primary

Measure	Time frame
The primary outcome was quality of life as measured with the subscale distance activities and the composite scale of the NEI-VFQ-25	—

Secondary

Measure	Time frame
Secondary outcomes were visual acuity (ETDRS) and contrast sensitivity (Pelli-Robson) measures with or with the MD-clip. Burden was measured using the EQ-5D-5L	—

Contacts

Public ContactMartijn Visser

Department of Psychiatry, section Medical Psychology and Psychotherapy, Erasmus Medical Center

E-Mail m.s.visser@erasmusmc.nlTel. +31 10 704 38 10

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)